Acuity RM Group 2.6p £4.3m (ACRM.L)
The Company which owns Acuity Risk Management Limited, today releases the interim results for the six months ended 30 June 2024. Revenue increased £1.0m (H1 2023 actual for six months: £0.9m), cash balance of £1.86m (31 December 2023: £0.1m) and a sales pipeline of £7.9m (30 June 2023: £4.4m). There is much work to do to enable the Company to achieve its targets and potential. The Board is implementing programmes to improve marketing and sales ability to seize upcoming growth opportunities and the products to broaden and strengthen their appeal. Looking forward, the Board is confident that its initiatives will deliver benefits and drive growth.
Clontarf Energy 0.06p £4.3m (CLON.L)
The energy Company focused on clean Bolivian Lithium brines, as well as petroleum in Australia and Africa announces its unaudited financial results for the six months ended 30 June 2024. Loss before tax increased to £403k (30 June 23: £288k), cash and cash equivalents increased to £601k (30 June 23: £381k) and the EU is building a 'Team Europe' approach, passing a Critical Resource Minerals Act, and deploying circa EUR 4bn from the Global Gateway fund. Bolivia commits itself to accelerating its battery-grade Lithium exports, with senior Government personnel changes announced, early contract negotiations and reform of the Lithium Law.
Facilities by ADF 54p £43.7m (ADF.L)
The provider of premium serviced production facilities to the UK film and high-end television industry (HETV) announces its unaudited half year results for the six months ended 30 June 2024. Revenue decreased to £15.2m (H1 2023: £21.8m), Adjusted EBITDA decreased to £2.5m (H1 2023: £5.8m) and the cash and cash equivalents decreased to £1.68m (31 December 2023: £3.53m). Trading in H2-FY24 continues to improve and over the course of the period they expect market conditions will return to be more in line with pre-strike levels, providing us confidence in delivering results for FY24 in line with market expectations.
Kinovo 69.5p £42.3m ( KINO.L)
The specialist property services group has announced that it has been awarded a new contract worth up to £12m over 18 months by the London Borough of Hackney. It was awarded through the National Housing Maintenance Forum's Net Zero Carbon Framework for a range of Net Zero Carbon works including the installation of triple-glazed windows, energy efficient boilers and upgrading renewable energy systems, covering over 300 properties. This will contributor to the March 2025 year-end ahead of which its Interims are due to be reported in November.
Kromek Group 5.65p £36.2m (KMK.L)
The developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segment announces that it has been awarded a contract worth £2.0m by the UK Ministry of Defence (MOD) for the supply of nuclear radiation detectors and ancillary products. The contract is to be delivered in the Group's current financial year ending 30 April 2025. The contract is for the supply of the Group's D5 RIID, a handheld, highly-sensitive gamma and neutron detector, along with the Group's Alpha Beta probe attachment and other associated products. Launched in November 2023, the Alpha Beta probe connects directly to the D5 RIID to enable alpha and beta radiation to be detected, allowing the single, small form factor upgraded device to detect all types of radioactive material.
Made Tech Group 16p £24.7m (MTEC.L)
The provider of digital, data and technology services has announced that it has been awarded a contract from the Department for Education worth around £13.2m over four-years with an option for a fifth year worth a further £3.3m. This contract’s initial contribution is expected to be recognised in the current financial year helping to underpin 2025 forecasts. Its initial focus is the delivery of the Reception Baseline Assessment, a new government initiative to monitor pupil progress, scheduled for rollout in April 2025. Finals to May 2024 are due to be reported shortly.
Mosman Oil and Gas Limited 0.036p £5.4m (MSMN.L)
The helium, hydrogen and hydrocarbon exploration, development and production Company announces that it has raised £1.5m by way of a placing and subscription of ordinary shares at a price of 0.035p per share. Directors Andy Carroll and Nigel Harvey will subscribe for a total of £15,000 at the Issue Price. The net proceeds of the Fundraise will enable Mosman to pursue and progress identified helium projects, with a view to expanding the Company's helium portfolio and provide additional working capital.
Sareum Holdings * 28p £30.2m (SAR.L)
A clinical-stage biotechnology Company developing next-generation kinase inhibitors for autoimmune disease and cancer announces that it has received a Notice of Allowance from the China National Intellectual Property Administration. This notice pertains to a patent application protecting certain crystalline forms of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a wide range of autoimmune diseases. The Chinese patent, will provide significant protection on several crystalline forms of SDC-1801 and in the methods of their preparation. The Company anticipates the Chinese patent to be granted by the end of 2024, subject to the fulfilment of certain formalities. This is the first patent allowance protecting crystalline forms of SDC-1801 in any territory. Patent applications in other key territories, including the US, Europe, Japan are under review.
Science In Sport 25p £57.6m (SIS.L)
The premium performance nutrition Company serving elite athletes, sports enthusiasts, and the active lifestyle community announces it's unaudited interim results for the six months to 30 June 2024. Revenue decreased to £25.7m (H1 2023: £34.4m), underlying EBITDA increased to £2.0m (H1 2023: £1.1m) and the cash and cash equivalents increased to £1.53m (H1 2023: £1.23m). While cognisant of ongoing macro dynamics, SiS's strong market position and brand recognition, communicated plans for controlled investment in to working capital, market penetration and improvements to the manufacturing process facilities give the Board confidence for FY24 and beyond.
Synectics 237p £42.2m (SNX.L)
The advanced security and surveillance systems Company provides an update on trading for the year ending 30 November 2024, following the conclusion of its third quarter, ended 31 August 2024. The Company confirms that trading in the third quarter of the year was positive, with continued momentum across its key markets. Order intake remains strong and recent contract wins have included a $1.2m contract for the installation of a new security and surveillance system at a casino resort in the Philippines, further contract wins with Saudi Aramco, and a strategically important order for the Company's first installation, of a new security and surveillance system for a casino resort, in Cambodia. As a result, the Board expects the Company's underlying PBT for FY 2024 to be materially ahead of market expectations. The Company continues to focus on further strengthening its already healthy FY 2025 order book.
.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
